Indivior (INDV) said Thursday it expects $1.13 billion to $1.20 billion for 2026 net revenue, reflecting expected revenue growth from its Sublocade treatment for opioid use disorder.
Analysts polled by FactSet expect $1.13 billion.
The company said it expects Sublocade net revenue to increase by 11% in 2026, to between $905 million to $945 million, driven by dispense unit growth and expected margin expansion.
Shares of Indivior were up more than 1% in recent premarket activity Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments